Please login to the form below

Not currently logged in
Email:
Password:

HPV vaccine

This page shows the latest HPV vaccine news and features for those working in and with pharma, biotech and healthcare.

Analysts look beyond Keytruda in Merck’s future

Analysts look beyond Keytruda in Merck’s future

Human papillomavirus (HPV) vaccine Gardasil was up a third to $835m, and there were good performances for cancer drugs Lynparza (olaparib) and Lenvima (lenvatinib), partnered with AstraZeneca and Eisai, respectively.

Latest news

  • MSD supports Jabs for the Boys campaign MSD supports Jabs for the Boys campaign

    Additionally, HPV Action has also been championing the importance of making the HPV vaccine available to men, which was the chief issue of the campaign. ... step towards increasing public awareness of HPV and it is crucial that men, boys and their

  • AZ adds cancer vaccine to immuno-oncology portfolio AZ adds cancer vaccine to immuno-oncology portfolio

    AZ's MedImmune unit is paying $27.5m upfront and $700m in developmental and commercial milestones for global rights to Inovio's human papillomavirus (HPV) vaccine INO-3112, which is in ... MedImmune will test the DNA vaccine - which targets cancers

  • EMA launches review of cervical cancer vaccine safety EMA launches review of cervical cancer vaccine safety

    The HPV vaccines - GlaxoSmithKline's Cervarix and Sanofi Pasteur MSD's Gardasil/Silgard and just-approved new version Gardasil 9 - have been approved for nearly 10 years with some 165m doses ... The EMA said: “Both conditions can occur in

  • Terrence Higgins Trust pushes for HPV vaccine for men Terrence Higgins Trust pushes for HPV vaccine for men

    Charity speaks out to coincide with European Immunisation Week.  . UK HIV and sexual health charity Terrence Higgins Trust has urged for the HPV vaccine to be extended to men who have ... Dr Shaun Griffin, executive director of external affairs at

  • Pfizer's Prevenar 13 price cut slammed by MSF Pfizer's Prevenar 13 price cut slammed by MSF

    Pfizer has reduced the price of its pneumococcal vaccine Prevenar 13 for an immunisation programme targeting low-income countries, but has been criticised for not going far enough. ... The US pharma giant said it would cut the price of Prevenar 13

More from news
Approximately 1 fully matching, plus 46 partially matching documents found.

Latest Intelligence

  • Immunisation politicised Immunisation politicised

    Reshaping the HPV vaccine in Austria. While swift in other European countries, implementation took several years in Austria. ... Many countries objected to the HPV vaccine yet the vaccine was introduced rather rapidly in most countries.

  • Country report: The healthcare market in Japan Country report: The healthcare market in Japan

    Diovan. valsartan. Novartis. Hypertension. 4. Cervarix. human papillomavirus (HPV) vaccine. GlaxoSmithKline. ... HPV. 5. Lipitor. atorvastatin. Pfizer. Cholesterol lowerer. IMS Health Japan (July to September 2011, Q3).

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest from PMHub

  • Understanding the "Big Picture"

    A good example of this “Risk-awareness thinking” would be the impact of the cervical cancer vaccine to address human papilloma virus (HPV). ... Unlike the majority of diseases which have an incidence population continuously contributing to the

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Makara Health

Independent healthcare communications agency with a passion to develop inspirational ideas that create sustained and positive change. Whether it is...

Latest intelligence

Empowered patients: shaking the foundations of healthcare
Precision medicine represents a new paradigm in healthcare.This new approach to treating and preventing disease views the patient holistically, analysing their genes, environment and lifestyle, and using this information to...
A uniquely English genomic medicine service
The UK National Health Service is developing one standardised approach to embedding precision medicine across the whole of England. Blue Latitude Health speaks to Dr Tom Fowler, Deputy Chief Scientist...
Blended Intelligence
Data is the most valued commodity of the modern world. For P&P it's all about the application....

Infographics